Bioinvent Terminates Current BI-505 Phase II Study

BioInvent International AB (OMXS: BINV) is focused on developing a first-in-class and best-in-class pipeline of antibody …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
612